Zimbabwe has turned down a major US healthcare agreement worth $367m (272 million pounds) over five years due to Washington's demand for sensitive data.
This move became public following a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesman has since clarified that the US was demanding access to biological samples for research and profit but was unwilling to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further negotiations to find a agreement agreeable to all parties so the country's vital HIV programme can proceed.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court blocked a related deal with the US following legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral deals to boost transparency and accountability.
Based on reports, 16 nations in Africa have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, without any equivalent promise of access to any medical innovations – such as new medicines or tests – that might result from that provided information," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our people if a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems previously set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This mechanism is intended to ensure that when a nation contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We welcome further discussions with our US partners on how subsequent collaboration could be designed in a way that respects the independence and interests of both nations."
Medical Community Response
Medical experts expressed it acknowledged the official position, but recommended that negotiations should continue considering a large portion of the country's HIV programmes depended on international support.
"Where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," it commented.
The situation emphasises the ongoing challenges between accepting much-needed foreign assistance and safeguarding local interests in an increasingly data-driven world.